VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Adrian Wiestner on RESONATE II Trial

Adrian Wiestner, MD, PhD
Published: Wednesday, Jun 17, 2015



Adrian Wiestner, MD, PhD, Senior Investigator, Laboratory of Lymphoid Malignancies, National Institutes of Health, National Heart, Lung, and Blood Services discusses the findings of the RESONATE II trial, which looked at chlorambucil versus ibrutinib as first-line therapy in patients older than 65 with chronic lymphocytic leukemia (CLL).

Preliminary results from the trial show an improved overall survival and overall response rate with ibrutinib when compared to chlorambucil. Given all the ibrutinib data that has already been presented, those results are not surprising, but a full understanding cannot be determined until all the data is released, says Wiestner.

Even without the complete data, it is clear that studies like RESONATE II demonstrate a shift in the future treatment of CLL, says Wiestner.

Single-agent, targeted therapies like ibrutinib may now be the backbone of therapy for CLL patients.

The question will now become how far can a single agent go, and what the right combinations are to make the best of it, says Wiestner.

<<< View more from the 13th International Conference on Malignant Lymphoma



Adrian Wiestner, MD, PhD, Senior Investigator, Laboratory of Lymphoid Malignancies, National Institutes of Health, National Heart, Lung, and Blood Services discusses the findings of the RESONATE II trial, which looked at chlorambucil versus ibrutinib as first-line therapy in patients older than 65 with chronic lymphocytic leukemia (CLL).

Preliminary results from the trial show an improved overall survival and overall response rate with ibrutinib when compared to chlorambucil. Given all the ibrutinib data that has already been presented, those results are not surprising, but a full understanding cannot be determined until all the data is released, says Wiestner.

Even without the complete data, it is clear that studies like RESONATE II demonstrate a shift in the future treatment of CLL, says Wiestner.

Single-agent, targeted therapies like ibrutinib may now be the backbone of therapy for CLL patients.

The question will now become how far can a single agent go, and what the right combinations are to make the best of it, says Wiestner.

<<< View more from the 13th International Conference on Malignant Lymphoma


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x